Dr. Ugolkov is a Research Assistant Professor in the Center for Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center at Northwestern University and is a recognized expert on GSK-3 research in oncology.  Through his research, Dr. Ugolkov identified GSK-3 as a viable new therapeutic target in human cancer. Dr. Ugolkov brings extensive experience in clinical oncology, pathology and cancer research including establishment of heterotopic, orthotopic and metastatic xenograft tumor models. He is widely published in peer reviewed journals on the identification of new therapeutic targets in human cancer, and in pre-clinical testing of new anticancer drugs including GSK-3 inhibitors.

 Dr. Ugolkov is a Research Assistant Professor in the Center for Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center at Northwestern University and is a recognized expert on GSK-3 research in oncology.  Through his research, Dr. Ugolkov identified GSK-3 as a viable new therapeutic target in human cancer. Dr. Ugolkov brings extensive experience in clinical oncology, pathology and cancer research including establishment of heterotopic, orthotopic and metastatic xenograft tumor models. He is widely published in peer reviewed journals on the identification of new therapeutic targets in human cancer, and in pre-clinical testing of new anticancer drugs including GSK-3 inhibitors.